A phase 3 trial (LITESPARK‑022) reported that adding the HIF‑2α inhibitor belzutifan to pembrolizumab improved disease‑free survival in patients with clear‑cell renal cell carcinoma at high risk of recurrence after surgery. Trial sponsors presented preliminary event‑driven data showing a statistically significant delay in recurrence relative to control. The lead result centers on recurrence‑free survival rather than overall survival, and full survival follow‑up remains pending.